Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus.

Atherosclerosis - 1 May 2002

Schweitzer Morris, Tessier Daniel, Vlahos William D, Leiter Lawrence, Collet Jean Paul, McQueen Matthew J, Harvey Laurent, Alaupovic Petar

Abstract excerpt

The effects of pravastatin (pravachol) compared with gemfibrozil on cholesterol-rich and trigylceride-rich lipoproteins were evaluated in this multi-centered trial. Following an 8-12 week prerandomization phase, 136 patients with NIDDM and hypercholesterolemia were randomized to receive either pravastatin 40 mg or gemfibrozil 1200 mg daily for 16 weeks. The reduction of total cholesterol (TC), betaquant LDL and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoproteins
Share to Cholesterol, VLDL

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Double-Blind Method

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipoproteinemias

Share to Hypolipidemic Agents

Share to Patient Compliance

Share to Pravastatin

Source

Identifiers

PMID: 11947915
DOI: 10.1016/s0021-9150(01)00700-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus.PMID 11947915Read ↗

Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.Semantic proximity Read ↗

A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.Semantic proximity Read ↗

Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.Semantic proximity Read ↗

Co-administration of vitamin E and atorvastatin improves insulin sensitivity via peroxisome proliferator-activated receptor γ in hyperlipidemic type 2 diabetic patients: a randomized double-blinded clinical trialSemantic proximity Read ↗

Treatment of patients with familial defective apolipoprotein B-100 with pravastatin and gemfibrozil: a two-period cross-over study.Semantic proximity Read ↗

The role of fat tissue in the cholesterol lowering and the pleiotropic effects of statins--statins activate the generation of metabolically more capable adipocytes.Semantic proximity Read ↗

Risk reductions for cardiovascular disease with pravastatin treatment by dyslipidemia phenotype: a post hoc analysis of the MEGA Study.Semantic proximity Read ↗

Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients.Semantic proximity Read ↗

Duality of statin action on lipoprotein subpopulations in the mixed dyslipidemia of metabolic syndrome: Quantity vs quality over time and implication of CETP.Semantic proximity Read ↗

Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia.Semantic proximity Read ↗

Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.Semantic proximity Read ↗

Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.